Characteristics | (N, %) |
Age, years (median, range) | 64, 38–81 |
Co-morbidity (Charlson Comorbidity Index*) | |
0 | 8 (8.5) |
1–2 | 52 (55.3) |
≥3 | 34 (36.2) |
Previous lines of chemotherapy | |
2 | 64 (68.1) |
3 | 17 (18.1) |
≥4 | 13 (13.8) |
Debulking surgery at relapse | |
No | 87 (92.6) |
Yes, preceding last line of chemotherapy | 4 (4.3) |
Yes, not preceding last line of chemotherapy | 3 (3.2) |
Type of chemotherapy preceding niraparib | |
Platinum combination | 87 (92.6) |
Platinum single | 6 (6.4) |
Non-platinum | 1 (1.1) |
Previous bevacizumab treatment | |
Yes | 44 (46.8) |
No | 50 (53.2) |
Response of chemotherapy preceding niraparib† | |
CR | 11 (11.7) |
PR | 73 (77.7) |
SD | 6 (6.4) |
Non-evaluable‡ | 4 (4.3) |
CA125 level | |
≤35 kU/L | 54 (57.4) |
>35 kU/L | 40 (42.6) |
Start dosage | |
200 mg | 29 (30.9) |
300 mg | 65 (69.1) |
Weight | |
<77 kg | 69 (73.4) |
≥77 kg | 25 (26.6) |
*Age adjusted.
†Investigator assessed.
‡No computed tomography scan performed after surgery with no residual tumor.
CR, complete response; PR, partial response; SD, stable disease.